BWAY - BrainsWay: Deep TMS Deep Undervaluation

BrainsWay (BWAY) appears deeply undervalued given its current high growth rate, clear path to profitability and large addressable market. Although BrainsWay is not currently the market leader in the space, they have superior technology to competitors and they are focused on obtaining approval to treat a wider range of conditions. Results from clinical trials treating Post-Traumatic Stress Disorder (PTSD) and nicotine addiction (expected in the 2H 2019) or reimbursement approval for the treatment of Obsessive-Compulsive Disorder (OCD) could be catalysts for a significant repricing of the company.

BrainsWay is an Israeli company founded